The Effect of a Novel Joint Distraction Knee Orthosis for Treating Medial Knee Osteoarthritis

November 11, 2026 updated by: Icarus Medical Innovations

The Effect of a Novel Joint Distraction Knee Orthosis for Treating Medial Knee Osteoarthritis

Study Overview

Status

Not yet recruiting

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Virginia
      • Charlottesville, Virginia, United States, 22902
        • Icarus Medical Innovations
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 30-70, as significant knee OA is very common for people under 30, and would be more likely correlated to trauma.
  • Able to ambulate with or without assistive devices
  • Body-mass index (BMI) under 35. This is to minimize the effect of the variable of how the brace fits on the patient. The finding of pain relief will extrapolate to any BMI.
  • Willingness and ability to comply with scheduled visits and study procedures
  • Willingness and ability to fill out patient questionnaires written in English
  • Ability to provide informed consent
  • Clinical diagnosis of medial or lateral compartment knee osteoarthritis requiring a KO.
  • Subject is suitable for unilateral bracing

Exclusion Criteria:

  • Significant cognitive impairment interfering with study assessments
  • Active infections or wounds at the foot or leg
  • Severe spasticity that limits brace fitting or functioning
  • History of severe lower limb deformities that would preclude brace use
  • History of major joint surgery or joint implants, such as total knee replacement
  • Other neurological or musculoskeletal conditions unrelated to the lower limbs that significantly impact gait
  • Non-ambulatory
  • Inability to travel for study procedures or fill out required surveys
  • Medical conditions of interest
  • Pregnant women
  • Prisoners
  • Clinical diagnosis of knee osteoarthritis that is not specific to the knee's medial or lateral compartment (multicompartmental, or patellofemoral knee osteoarthritis)
  • Self-reported pain score of less than 3 out of 10 in the medial compartment.
  • Varus or valgus deformity greater than 12°
  • Inability to read/write/communicate in English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: The Effect of a Novel Joint Distraction Knee Orthosis for Treating Medial Knee Osteoarthritis

Patients experiencing unicompartment (medial or lateral) osteoarthritis will receive Icarus Adonis Joint Distraction brace. Patients will wear the brace for 12 weeks and document how often they wear the brace and their pain scores. Patients will fill out outcome surveys at 2, 4, 6, 8, and 12 weeks.

Patients will receive Icarus Adonis Joint Distraction brace.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knee Injury and Osteoarthritis Outcome Score (KOOS)
Time Frame: Baseline, 2, 4, 8, 12 weeks

Scored 0 to 100, where 0 represents total knee disability and 100 represents perfect knee

Baseline, 2, 4, 8, 12 weeks
European Quality of Life-5 Dimensions (EQ-5D-5L)
Time Frame: Baseline, 2, 4, 8, 12 weeks.

0 to 1, where 1 is perfect health

Baseline, 2, 4, 8, 12 weeks.
Visual Analogue Scale (VAS)
Time Frame: Baseline, 2, 4, 8, 12 weeks.

0-100, zero meaning no pain, 10 meaning severe pain

Baseline, 2, 4, 8, 12 weeks.
Functional Mobility Assessments
Time Frame: Baseline, 2, 4, 8, 12 weeks

6 minute walk test

Baseline, 2, 4, 8, 12 weeks
Functional Mobility Assessment
Time Frame: Baseline, 2, 4, 8, 12 weeks

5 times Sit to Stand test

Baseline, 2, 4, 8, 12 weeks
Functional Mobility Assessment
Time Frame: Baseline, 2, 4, 8, 12 weeks

Timed Up and Go test

Baseline, 2, 4, 8, 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

February 18, 2026

First Submitted That Met QC Criteria

February 23, 2026

First Posted (Actual)

February 27, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

IPD must be deidentified according to UVA IRB standard. If this would be the case then we would plan to share IPD and publish this study.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe